Skip to main content
Top
Published in: Breast Cancer 3/2015

01-05-2015 | Special Article

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011

Authors: Junichi Kurebayashi, Yasuo Miyoshi, Takashi Ishikawa, Shigehira Saji, Tomoharu Sugie, Takashi Suzuki, Shunji Takahashi, Miwako Nozaki, Hiroko Yamashita, Yutaka Tokuda, Seigo Nakamura

Published in: Breast Cancer | Issue 3/2015

Login to get access

Abstract

Purposes

We conducted a study to analyze the clinicopathological characteristics of breast cancer in Japan registered to the Japanese Breast Cancer Registry of the Japanese Breast Cancer Society (JBCS). Trends in the management of breast cancer patients in Japan were also analyzed.

Patients and methods

More than 250,000 breast cancer patients were registered to the JBCS registry between 2004 and 2011. Demographic and clinicopathological factors in newly diagnosed primary breast cancer patients were registered to the JBCS through the Web-based system from affiliated institutes nationwide.

Results

Two distinct peaks were observed, in patients in their late 40s and early 60s, in the population-adjusted age distribution of breast cancer patients. An increased rate of screen-detected breast cancer may contribute to an earlier detection of breast cancer and increased rate of non-invasive ductal carcinoma. The positive rate of either ER or PgR appears to have increased in recent years. The annual rates of patients treated with breast-conserving surgery increased until 2006, but these increases stopped in 2007 and thereafter plateaued at approximately 60 %. The annual rates of patients treated with sentinel lymph node dissection alone have steadily increased. The annual rates of patients treated with preoperative trastuzumab plus chemotherapy have also increased, as well as those treated with postoperative aromatase inhibitors. The annual rates of patients treated with postoperative anthracycline-containing regimens have decreased, whereas those treated with postoperative taxane-containing regimens have increased. The postoperative use of trastuzumab has markedly increased since 2007.

Conclusion

Although this study was based on the registry database, several unique clinicopathological characteristics of breast cancer in Japan have been unveiled. Our results suggest that recent trends in the management of breast cancer patients in Japan were strongly followed by clinical evidence that originated from a number of clinical trials worldwide.
Appendix
Available only for authorised users
Literature
2.
go back to reference Tokuda Y. The Japanese Breast Cancer Society Breast Cancer Registry in the National Clinical Database: current status and future perspectives. Nihon Geka Gakkai Zasshi. 2014;115(1):17–21 (in Japanese).PubMed Tokuda Y. The Japanese Breast Cancer Society Breast Cancer Registry in the National Clinical Database: current status and future perspectives. Nihon Geka Gakkai Zasshi. 2014;115(1):17–21 (in Japanese).PubMed
3.
go back to reference Greene FL. Breast tumours. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002. p. 131–41. Greene FL. Breast tumours. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002. p. 131–41.
4.
go back to reference World Health Organization. Tumours of the Breast and Female Genital Organs. Oxford: Oxford University Press; 2003. World Health Organization. Tumours of the Breast and Female Genital Organs. Oxford: Oxford University Press; 2003.
5.
go back to reference Pant K, Dutta U. Understanding and management of male breast cancer: a critical review. Med Oncol. 2008;25(3):294–8.CrossRefPubMed Pant K, Dutta U. Understanding and management of male breast cancer: a critical review. Med Oncol. 2008;25(3):294–8.CrossRefPubMed
6.
go back to reference Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25(27):4210–6.CrossRefPubMed Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25(27):4210–6.CrossRefPubMed
7.
go back to reference Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000;88(12):2739–50.CrossRefPubMed Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000;88(12):2739–50.CrossRefPubMed
8.
go back to reference Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah population database. JAMA. 1993;270(13):1563–8.CrossRefPubMed Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah population database. JAMA. 1993;270(13):1563–8.CrossRefPubMed
10.
go back to reference Kim Z, Min SY, Yoon CS, Lee HJ, Lee JS, Youn H, et al. Korean Breast Cancer Society. The basic facts of Korean breast cancer in 2011: results of a nationwide survey and breast cancer registry database. J Breast Cancer. 2014;17(2):99–106.CrossRefPubMedCentralPubMed Kim Z, Min SY, Yoon CS, Lee HJ, Lee JS, Youn H, et al. Korean Breast Cancer Society. The basic facts of Korean breast cancer in 2011: results of a nationwide survey and breast cancer registry database. J Breast Cancer. 2014;17(2):99–106.CrossRefPubMedCentralPubMed
11.
go back to reference Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, ATAC Trialists’ Group, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–9.CrossRefPubMed Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, ATAC Trialists’ Group, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–9.CrossRefPubMed
12.
go back to reference Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013;24(10):2506–14.CrossRefPubMedCentralPubMed Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013;24(10):2506–14.CrossRefPubMedCentralPubMed
14.
go back to reference Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, Teh BS. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer. 2014;111(3):619–22.CrossRefPubMed Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, Teh BS. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer. 2014;111(3):619–22.CrossRefPubMed
15.
go back to reference Brouckaert OI, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol. 2012;23(10):2578–84.CrossRefPubMed Brouckaert OI, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol. 2012;23(10):2578–84.CrossRefPubMed
16.
go back to reference Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430–41.CrossRefPubMed Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430–41.CrossRefPubMed
17.
go back to reference Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289(11):1421–4.CrossRefPubMed Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289(11):1421–4.CrossRefPubMed
18.
go back to reference Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumors: pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003. p. 13–59. Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumors: pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003. p. 13–59.
19.
go back to reference Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, et al. Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. Ann Oncol. 2011;22:1318–25.CrossRefPubMed Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, et al. Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. Ann Oncol. 2011;22:1318–25.CrossRefPubMed
20.
go back to reference Hosoda M, Yamamoto M, Nakano K, Hatanaka K, Takakuwa E, Hatanaka Y, et al. Differential expression of progesterone receptor, FOXA1, GATA3 and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2014;144:249–61.CrossRefPubMed Hosoda M, Yamamoto M, Nakano K, Hatanaka K, Takakuwa E, Hatanaka Y, et al. Differential expression of progesterone receptor, FOXA1, GATA3 and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2014;144:249–61.CrossRefPubMed
21.
go back to reference Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094–101.CrossRefPubMedCentralPubMed Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094–101.CrossRefPubMedCentralPubMed
22.
go back to reference Ko BS, Noh WC, Kang SS, Park BW, Kang EY, Paik NS, et al. Korean Breast Cancer Society. Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database. J Breast Cancer. 2012;15:393–400.CrossRefPubMedCentralPubMed Ko BS, Noh WC, Kang SS, Park BW, Kang EY, Paik NS, et al. Korean Breast Cancer Society. Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database. J Breast Cancer. 2012;15:393–400.CrossRefPubMedCentralPubMed
23.
go back to reference Leong SPL, Shen Z-Z, Liu T-J, Agarwal G, Tajima T, Paik N-S, Sandelin K, et al. Is breast cancer the same disease in Asian and Western Countries? World J Surg. 2010;34:2308–24.CrossRefPubMedCentralPubMed Leong SPL, Shen Z-Z, Liu T-J, Agarwal G, Tajima T, Paik N-S, Sandelin K, et al. Is breast cancer the same disease in Asian and Western Countries? World J Surg. 2010;34:2308–24.CrossRefPubMedCentralPubMed
24.
go back to reference Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol. 2009;16:687–96.CrossRefPubMed Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol. 2009;16:687–96.CrossRefPubMed
25.
go back to reference Jagsi R, Abrahams P, Morrow M, Hawlet ST, Griggs JJ, Graff JJ, et al. Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer. J Clin Oncol. 2010;28:2396–403.CrossRefPubMedCentralPubMed Jagsi R, Abrahams P, Morrow M, Hawlet ST, Griggs JJ, Graff JJ, et al. Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer. J Clin Oncol. 2010;28:2396–403.CrossRefPubMedCentralPubMed
Metadata
Title
Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011
Authors
Junichi Kurebayashi
Yasuo Miyoshi
Takashi Ishikawa
Shigehira Saji
Tomoharu Sugie
Takashi Suzuki
Shunji Takahashi
Miwako Nozaki
Hiroko Yamashita
Yutaka Tokuda
Seigo Nakamura
Publication date
01-05-2015
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2015
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0599-6

Other articles of this Issue 3/2015

Breast Cancer 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine